ARQ Wealth Advisors LLC Buys New Position in Becton, Dickinson and Company $BDX

ARQ Wealth Advisors LLC bought a new stake in Becton, Dickinson and Company (NYSE:BDX) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 3,340 shares of the medical instruments supplier’s stock, valued at approximately $625,000.

Several other hedge funds also recently made changes to their positions in the business. Focus Financial Network Inc. grew its stake in shares of Becton, Dickinson and Company by 2.2% in the third quarter. Focus Financial Network Inc. now owns 2,692 shares of the medical instruments supplier’s stock worth $504,000 after purchasing an additional 58 shares during the last quarter. Phillips Wealth Planners LLC increased its holdings in Becton, Dickinson and Company by 2.7% in the third quarter. Phillips Wealth Planners LLC now owns 2,241 shares of the medical instruments supplier’s stock valued at $430,000 after purchasing an additional 58 shares during the period. CX Institutional raised its position in Becton, Dickinson and Company by 3.6% during the 3rd quarter. CX Institutional now owns 1,731 shares of the medical instruments supplier’s stock worth $324,000 after purchasing an additional 60 shares during the last quarter. KCM Investment Advisors LLC lifted its holdings in Becton, Dickinson and Company by 4.1% during the 3rd quarter. KCM Investment Advisors LLC now owns 1,525 shares of the medical instruments supplier’s stock worth $285,000 after buying an additional 60 shares during the period. Finally, Gamco Investors INC. ET AL lifted its holdings in Becton, Dickinson and Company by 0.6% during the 3rd quarter. Gamco Investors INC. ET AL now owns 9,570 shares of the medical instruments supplier’s stock worth $1,791,000 after buying an additional 60 shares during the period. 86.97% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bertram L. Scott sold 953 shares of the business’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the transaction, the director owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 2,787 shares of company stock valued at $551,391 over the last 90 days. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.9%

BDX stock opened at $161.64 on Wednesday. The stock has a 50-day simple moving average of $188.36 and a two-hundred day simple moving average of $189.53. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The firm has a market capitalization of $46.03 billion, a PE ratio of 26.37, a PEG ratio of 11.62 and a beta of 0.24. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. The firm had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The company’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same period in the prior year, the firm posted $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company announced that its Board of Directors has initiated a share buyback plan on Tuesday, January 27th that allows the company to buyback $10.00 million in shares. This buyback authorization allows the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be issued a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 68.52%.

Analyst Ratings Changes

Several brokerages have recently weighed in on BDX. Royal Bank Of Canada set a $172.00 price target on Becton, Dickinson and Company in a research note on Tuesday, February 10th. Zacks Research lowered Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 11th. Stifel Nicolaus upped their target price on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Jefferies Financial Group decreased their target price on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a research report on Tuesday, February 10th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 10th. Five analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $195.46.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.